CLLS
CellectisCLLS
CLLS
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
100% more call options, than puts
Call options by funds: $6K | Put options by funds: $3K
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
10% more capital invested
Capital invested by funds: $20.9M [Q3] → $23M (+$2.1M) [Q4]
7% more funds holding
Funds holding: 27 [Q3] → 29 (+2) [Q4]
4.15% more ownership
Funds ownership: 13.55% [Q3] → 17.7% (+4.15%) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
Research analyst outlook
We haven’t received any recent analyst ratings for CLLS.
Financial journalist opinion
Based on 3 articles about CLLS published over the past 30 days
Neutral
Seeking Alpha
1 week ago
Cellectis S.A. (CLLS) Q4 2024 Earnings Call Transcript
Cellectis S.A. (NASDAQ:CLLS ) Q4 2024 Earnings Conference Call March 14, 2025 8:00 AM ET Company Participants Arthur Stril - CFO and Chief Business Officer Andre Choulika - CEO Adrian Kilcoyne - CMO Conference Call Participants Gena Wang - Barclays Jack Allen - Baird Sebastiaan van der Schoot - Kempen Silvan Tuerkcan - Citizens Jack Allen - Baird Hangfei Fu - Jefferies Operator Good day, everyone, and welcome to today's Cellectis Full Year 2024 Earnings Conference Call.
Neutral
GlobeNewsWire
2 weeks ago
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update
○ UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) granted by FDA and ODD granted by the European Commission to UCART22 for the treatment of ALL.
Neutral
GlobeNewsWire
2 weeks ago
Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and full year 2024 ending December 31, 2024 on Thursday, March 13, 2025 after the close of the US market.
Neutral
GlobeNewsWire
1 month ago
Cellectis Presents ‘Smart CAR T' Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, showcases an innovative strategy for T cell engineering that leverages the pro-inflammatory properties of interleukin 2 (IL-2) with the objective to enhance CAR T cell efficacy against solid tumors, at the American Association for Cancer Research – Immuno-oncology (AACR-IO), taking place on February 23-26, 2025 in Los Angeles, CA.
Positive
Seeking Alpha
3 months ago
Cellectis: Poised To Start Answering Questions In 2025
Cellectis S.A.'s pipeline updates highlight promising advancements in engineered, allogeneic cell therapies. The financial overview indicates a strong cash position, but ongoing R&D expenses pose a risk to its longevity. Key data updates are coming in 2025 that will give us a look at their lead program in a larger population.
Neutral
GlobeNewsWire
3 months ago
Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it has drawn down the final tranche of €5 million (“Tranche C”) under the credit facility agreement for up to €40 million entered into with the European Investment Bank (the “EIB) on December 28, 2022 (the "Finance Contract"). With the drawdown of Tranche C, the Company has drawn down the full €40 million available under the Finance Contract. Tranche C is expected to be disbursed by the EIB by December 18, 2024. The Company plans to use the proceeds of Tranche C towards the development of its pipeline of allogeneic CAR T-cell product candidates: UCART22 and UCART20x22.
Neutral
GlobeNewsWire
4 months ago
Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting
NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that pre-clinical data to enhance CAR T cell activity against solid tumors while preventing potential toxicity, will be presented at the Society for Immunotherapy of Cancer's 39th Annual Meeting (SITC), that will take place on November 6-10, 2024 in Houston, Texas.
Neutral
Seeking Alpha
4 months ago
Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript
Cellectis S.A. (NASDAQ:CLLS ) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET Company Participants Arthur Stril - Interim Chief Financial Officer Andre Choulika - Chief Executive Officer Adrian Kilcoyne - Chief Medical Officer Conference Call Participants Gena Wang - Barclays Jack Allen - Baird Ashiq Mubarack - Citi Kuan-Hung Lin - Wells Fargo Luisa Morgado - Van Lanschot Kempen Silvan Tuerkcan - Citizens JMP Operator Good morning, everyone, and welcome to the Cellectis Third Quarter 2024 Earnings Call.
Neutral
GlobeNewsWire
4 months ago
Cellectis Provides Business Updates and Financial Results for Third Quarter 2024
NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided business updates and reported financial results for the nine-month period ending September 30, 2024.
Neutral
GlobeNewsWire
4 months ago
Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter 2024 ending September 30, 2024 on Monday, November 4, 2024 after the close of the US market.
Charts implemented using Lightweight Charts™